The European Union Drug Enforcement Agency is examining the cases of blood clots in four people who have received the Johnson & Johnson coronavirus vaccine, although there is still no link between the two.
The European Medicines Agency (EMA) said on Friday that serious cases of “unusual blood clots with low platelets” had been reported in four people receiving Johnson & Johnson inoculation. according to Reuters.
Three of the cases occurred in the United States during the launch of the vaccine, while a person who participated in the Johnson & Johnson clinical trial died of a clotting disorder.
In accordance with Centers for Disease Control and Prevention (CDC), approximately 5 million people in the US have already received the Johnson & Johnson vaccine.
The company said in a statement on Friday that it is aware of the blood clot reports and is working with regulators to review safety data.
“At present, no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine,” Johnson & Johnson told Reuters.
Hill contacted the vaccine developer for more information.
The reports come because there has already been widespread concern about blood clots reported to people who received the AstraZeneca vaccine, which was not federally authorized for emergency use in the United States.
An EMA safety committee said so on Wednesday there was a “possible link” between inoculation of AstraZeneca and rare blood clots, but added that the benefits of receiving the vaccine outweigh the potential risks.
The committee said that Unusual blood clots with low platelets should be listed as very rare side effects of the vaccine, although it did not impose new restrictions on inoculation.
However, some European countries have imposed limits on the distribution of the AstraZeneca vaccine, including advising young age groups against receiving it.
Most cases of blood clots have been reported in women under the age of 60 within two weeks of receiving the AstraZeneca vaccine.
Johnson & Johnson and AstraZeneca vaccines are two of four that have been approved in Europe, although the launch of the single dose of Johnson & Johnson has not yet begun across the region.